Evidence Grade A — Regulatory approved. 102 published studies. 23 registered clinical trials.
Medically reviewed by a licensed medical professional
Loading...
Afamelanotide (sold as Scenesse) is a small implant placed under the skin that helps the body produce protective melanin pigment without needing sun exposure. It is approved for people with erythropoietic protoporphyria (EPP), a rare inherited condition where even brief exposure to light causes severe, burning pain. Before Scenesse, there was no approved treatment for EPP.
Afamelanotide is also known by these brand and alternate names:
102 published studies: 71 human, 1 animal, 4 in-vitro, 41 reviews
Afamelanotide is marketed as Scenesse (Clinuvel Pharmaceuticals, approved October 2019 in the US; previously approved in the EU in 2014). It is delivered as a bioresorbable subcutaneous implant administered every two months. Treatment is only available through a restricted distribution programme.
In clinical trials, EPP patients on afamelanotide could spend significantly more time in direct sunlight without pain. EPP is a debilitating condition where even brief light exposure can cause hours of burning pain, and prior to Scenesse there was no approved treatment. Afamelanotide is related to the research compound Melanotan I, but is the only version that has undergone full regulatory approval for a specific medical condition.
Afamelanotide activates melanocortin-1 receptors on melanocytes (the skin's pigment-producing cells), stimulating them to produce eumelanin — the dark, protective form of melanin. Crucially, this happens without UV exposure. In patients with EPP, a build-up of protoporphyrin in the skin causes excruciating pain when activated by light. The increased eumelanin acts as a natural light shield, absorbing the wavelengths that would otherwise trigger this toxic reaction, allowing patients to tolerate more light exposure without pain.
Clinical trials showed that EPP patients receiving afamelanotide could spend significantly more time outdoors without experiencing the debilitating pain that normally confines them indoors. For a condition with no other pharmacological treatment, this represented a meaningful improvement in quality of life. The implant is given every two months and is only available through a restricted distribution programme due to the tiny patient population. Afamelanotide is derived from the same family of melanocortin research as the unregulated tanning peptides Melanotan I and Melanotan II, but it is the only product from this lineage to have completed full regulatory approval for a specific medical condition. The manufacturer is exploring additional uses including vitiligo (a skin pigmentation disorder) and other conditions involving light sensitivity. The ultra-small patient population means the price is high, following the rare disease commercial model.
PeptideTrace tracks 23 registered clinical trials for Afamelanotide sourced from ClinicalTrials.gov.
Pharmacokinetics of Afamelanotide in Erythropoietic Protoporphyria Patients
A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo
Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP)
A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face
A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V
EMA Marketing Authorisation
FDA ORIG 1
FDA SUPPL 7
Afamelanotide is a 13-amino-acid linear peptide, a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) with Nle4 and D-Phe7 substitutions ([Nle⁴,D-Phe⁷]-α-MSH). These modifications increase potency 100–1,000-fold over native α-MSH and improve metabolic stability. Originally developed at the University of Arizona in the 1980s as 'Melanotan I.'
Afamelanotide activates melanocortin-1 receptors (MC1R) on melanocytes, stimulating eumelanin biosynthesis (the brown/black photoprotective pigment) independently of UV exposure. In patients with erythropoietic protoporphyria (EPP), accumulated protoporphyrin IX in the skin causes severe phototoxicity upon light exposure. Increased eumelanin levels provide a photoprotective barrier, absorbing visible light and reducing protoporphyrin-mediated skin damage.
Afamelanotide is marketed as Scenesse (Clinuvel Pharmaceuticals, FDA approved October 8, 2019) for increasing pain-free light exposure in adult patients with EPP. Delivered as a bioresorbable subcutaneous implant (16 mg rod, 1.7 cm length) inserted above the iliac crest, dissolving over 50–60 days. The US pivotal trial (N=93) showed a median increase of 64.1 hours of pain-free sun time versus 40.5 hours with placebo (+58%). Price: approximately $49,000 per implant (~$150,000/year). The US EPP patient population is estimated at approximately 5,000–10,000.
GHK has no pharmaceutical authorisation. Small cosmetic studies of the copper-complexed form (GHK-Cu) have reported improvements in skin appearance measures. No pharmaceutical clinical trials for injectable use have been completed. As with GHK-Cu (#85), the cosmetic evidence base for topical use should be distinguished from claims about injectable use. Gene expression profiling studies have reported broad effects, but observational genomic changes do not constitute evidence of therapeutic efficacy. This entry overlaps substantially with GHK-Cu (#85).
Argireline has no pharmaceutical authorisation. It is widely available as a cosmetic ingredient in over-the-counter skincare products. Small industry-sponsored studies have reported wrinkle depth reductions of 17–30% with topical application. The key scientific question is whether sufficient peptide penetrates intact skin to reach neuromuscular junctions and produce a meaningful effect. The molecule's size exceeds the conventional limit for transdermal absorption. Argireline's cosmetic use in formulated skincare products represents a fundamentally different risk profile from injectable use.
GHK-Cu has no pharmaceutical authorisation from any regulatory agency. It is widely available as a cosmetic ingredient in over-the-counter skincare products, where it is marketed for skin conditioning. A small study comparing GHK-Cu cream to vitamin C and retinoic acid creams reported improvements in skin appearance measures. No pharmaceutical clinical trials for injectable GHK-Cu have been completed. The compound's cosmetic use (topical, in formulated skincare products) should be clearly distinguished from its unregulated availability as an injectable research compound. These represent fundamentally different risk profiles.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
